Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
Type
Public
HQ
Waltham, US
Founded
2001
Size (employees)
17 (est)
Chiasma was founded in 2001 and is headquartered in Waltham, US
Report incorrect company information

Key People/Management at Chiasma

Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member

Chiasma Office Locations

Chiasma has offices in Ness Ziona and Waltham
Waltham, US (HQ)
250 275 Wyman St
Ness Ziona, IL
5 Golda Me'ir St
Show all (2)
Report incorrect company information

Chiasma Financials and Metrics

Chiasma Financials

USD

Net income (FY, 2017)

(26.8 m)

EBIT (FY, 2017)

(28.1 m)

Market capitalization (20-Apr-2018)

36.6 m

Cash (31-Dec-2017)

14.6 m
Chiasma's current market capitalization is $36.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

9.1 m

R&D expense

19 m31.3 m17.9 m

Operating expense total

19 m31.3 m28.1 m

EBIT

(35.4 m)(61.3 m)(28.1 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

2.5 m2.6 m

R&D expense

4.2 m4.4 m7.2 m14.8 m4.5 m4.7 m4.3 m

Operating expense total

7.6 m9.2 m17.2 m26.7 m9.4 m7.1 m6.9 m6.9 m

EBIT

(7.6 m)(9.2 m)(17.2 m)(26.7 m)(9.4 m)(7.1 m)(6.9 m)(6.9 m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

41 m37 m14.6 m

Inventories

2.3 m2.1 m

Current Assets

151.1 m95.1 m68.7 m

PP&E

676 k683 k193 k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

63.3 m140.9 m39.1 m30.5 m28.5 m19 m18.4 m12.1 m

Inventories

2.2 m

Current Assets

63.7 m164.2 m138.1 m118.1 m101.6 m86.8 m81.5 m75.3 m

PP&E

570.6 k573.5 k1.7 m2.6 m2.4 m646 k607 k
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(35.9 m)(61.1 m)(26.8 m)

Depreciation and Amortization

201 k433 k152 k

Inventories

(1.7 m)674 k

Accounts Payable

(161 k)1.8 m(1.6 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(12 m)(21.4 m)(17.2 m)(43.8 m)(9.4 m)(7 m)(6.8 m)

Depreciation and Amortization

98.6 k146.2 k59 k153 k

Inventories

2.2 m

Accounts Payable

358.5 k366 k3.9 m10.1 m1.2 m1.5 m2 m
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information